![](https://investorshub.advfn.com/uicon/754935.png?cb=1602980274)
Monday, October 12, 2020 9:06:34 AM
My understanding of these events:
Mipsagargin already had a successful phase 2 for hepatic cancer (https://pubmed.ncbi.nlm.nih.gov/31212948/) but It is speculated that they can’t start bigger trials until they can manufacture more due to limited availability of thapsigargin. (https://pubs.acs.org/doi/10.1021/cen-09519-notw4)
Their partner Phyton can make the difficult to produce chemical. (https://phytonbiotech.com/phyton-biotech-achieves-manufacturing-milestone-with-thapsigargin-the-active-agent-in-mipsagargin/j
Now that manufacturing capacity is ready there is a potential suspected reverse merger so they can capitalize on the value of having a phase 3 drug and being publicly traded. At the same time as patent submission by Phyton?
This is all just speculation on my part but very interesting timing.
Recent RBSH News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 09:19:43 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 08:36:33 PM
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM